TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05263167
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250ml sodium chloride 0.9% infusion bag intravenously once daily for 10 days.
Study: NCT04778579
Drug: ARI-0001 cells
Normalized name: OVIS ARIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z
Study: NCT05206370
Drug: Cytisinicline
Normalized name: cytisinicline
Approvals — FDA: no, EMA: no, PMDA: no
Description: film-coated oral tablets containing 3 mg cytisinicline
Study: NCT05206370
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: film-coated oral tablets containing matched placebo
Study: NCT06564987
Drug: 4% Articaine with 1:200,000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inferior Alveolar Nerve Block with 4% articaine
Study: NCT06564987
Drug: 2% lidocaine with 1:100,000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inferior Alveolar Nerve Block with 2% lidocaine
Study: NCT05479981
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by intravenous (IV) infusion.
Study: NCT05406401
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT05406401
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT05406401
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV or oral administration (per local guidelines)
Study: NCT06505395
Drug: SYHX2008 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will accept SYHX2008 injection by subcutaneous administration every cycle.
Study: NCT06505395
Drug: Sandostatin LAR@
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will accept Sandostatin LAR@ by intra-muscular administration every cycle.
Study: NCT06082843
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching Avenciguat (BI 685509)
Study: NCT06564935
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drops (identical to heptaminol drops, prepared by the hospital pharmacy) will be administered 1.5 to 2 hours before spinal anesthesia.
Study: NCT06283966
Drug: BGF MDI 320/14.4/9.6 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide, glycopyrronium, and formoterol fumarate pressurized inhalation suspension
Study: NCT06283966
Drug: GFF MDI 14.4/9.6 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium and formoterol fumarate pressurized inhalation suspension
Study: NCT06539195
Drug: DZD8586
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of DZD8586 at 25 mg
Study: NCT06539195
Drug: DZD8586
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of DZD8586 at 50 mg
Study: NCT06539195
Drug: DZD8586
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of DZD8586 at 75 mg
Study: NCT06493526
Drug: Withdrawal of calcineurin-inhibitor, continue on concentration-controlled mycophenolate mofetil and corticosteroids.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycophenolate mofetil dose will be optimized to an AUC12 of 60 h.mg/L, thereafter the calcineurin inhibitor will be withdrawn.
Study: NCT05360784
Drug: Lumify® (brimonidine tartrate ophthalmic solution 0.025%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumify® (brimonidine tartrate ophthalmic solution 0.025%). Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours apart for up to 4 consecutive weeks.
Study: NCT05660642
Drug: BPL-003
Normalized name: BANDAGE KIT,COMPRESSION LYMPHEDEMA#BPLEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental BPL-003 arms: will investigate one of two doses of BPL-003 (Part 1) and two doses of BPL-003 (Part 2)
Study: NCT06414031
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration
Study: NCT05014919
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT04708847
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous injection
Study: NCT04846998
Drug: BR9003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group B:~Once-daily oral administration of one BR9003 2mg tablet in the fasting state.~Treatment group C:~Once-daily oral administration of one BR9003 2mg tablet after a meal(high-fat meal) 30 minutes before the scheduled time of administration and finishing it.
Study: NCT04846998
Drug: BR9003A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group A:~Twice-daily oral administration of one BR9003A 1mg tablet in the fasting state
Study: NCT06549231
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one course of intravenous placebo of rituximab consisting of an infusion of 500 mL of saline (0.9% sodium chloride) infusion will be given at day 1, day 15 and week 24;
Study: NCT05781451
Drug: LY3361237
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive LY3361237 450mg subcutaneously every 2 weeks for a total of 12 weeks.
Study: NCT04724837
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo as per the arms they are randomized to.
Study: NCT05011383
Drug: High dose testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High dose testosterone is administered subcutaneously once monthly until progression or toxicity
Study: NCT05660109
Drug: TPM502
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPM502 contains 3 peptides each consisting of two overlapping T cell epitopes that encompass the major gluten epitopes for HLA-DQ2.5
Study: NCT05410223
Drug: Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yolk antibody: 7g\*10 board/box, produced by Beijing Yucheng Health Technology Co., Ltd.~Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd
Study: NCT05410223
Drug: IIaprazole, Amoxicillin/Clarithromycin/Furazolidone, Doxycycline, Bismuth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd
Study: NCT05410223
Drug: Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yolk antibody: 7g\*10 board/box, produced by Beijing Yucheng Health Technology Co., Ltd.~Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.
Study: NCT05410223
Drug: IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd
Study: NCT05645380
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2, IV
Study: NCT05645380
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2, IV
Study: NCT05938946
Drug: L608 Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects will be randomized at a ratio of 1:1 (for Sentinel dosing) followed by 5:1 for rest of the cohort to receive the assigned dose of L608 or placebo
Study: NCT05938946
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects will be randomized at a ratio of 1:1 (for Sentinel dosing) followed by 5:1 for rest of the cohort to receive the assigned dose of L608 or placebo
Study: NCT05677347
Drug: GSK3923868
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3923868 will be administered
Study: NCT05677347
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered
Study: NCT04908046
Drug: HMPL-295S1 with dose escalation stage of 5mg up to 200mg, then expansion stage with recommended dose of therapeutic cycle of 28 days .
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient starts the initial dose treatment with 5mg QD of HMPL-295S1, during dose escalation, single-dose PK evaluation will be carried out firstly in each dose group.~At the first therapeutic dose level, the single-dose treatment period is 5 days; from the 2nd dose level, the sponsor can determine the adjustment of single-dose treatment period to 3-5 days based on the available PK profile.~Subsequently, the patients will receive oral HMPL-295S1 QD continuously in a therapeutic cycle of 28 days (Day 1 - 28 of each cycle), until reaching the criteria on the end of treatment. The patients in RP2D extended cohort will enter the consecutive treatment period directly.
Study: NCT05724069
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.
Study: NCT05944341
Drug: articaine hydrochloride 4% with epinephrine 1:100 000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic agent
Study: NCT05944341
Drug: Lidocaine hydrochloride 2% with epinephrine 1:100 000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic agent
Study: NCT04905212
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection placebo. The injection site can be at the thigh, abdomen, or upper arm.
Study: NCT05294172
Drug: KL-A167
Approvals — FDA: no, EMA: no, PMDA: no
Description: KL-A167 4-6 cycles for combined therapy.KL-A167 maintenance.
Study: NCT05294172
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-6 cycles for combined therapy.Placebo maintenance.
Study: NCT05240560
Drug: BP1.3656
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine H3 receptor antagonist/inverse agonist
Study: NCT06493084
Drug: LAE102 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous drip or subcutaneous injection
Study: NCT05321602
Drug: LY03010 156 mg treatment group, deltoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
Study: NCT05321602
Drug: LY03010 156 mg treatment group, gluteal
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
Study: NCT05321602
Drug: LY03010 351 mg treatment group, deltoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
Study: NCT05321602
Drug: LY03010 351 mg treatment group, gluteal
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
Study: NCT04855435
Drug: MBS8(1V270)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational medicinal product will be administered IV by infusion. Subjects will be treated in cycles.
Study: NCT06456060
Drug: Alvogyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alvogyl soaked in a sterile gauze will be applied to cover the socket.
Study: NCT04518228
Drug: First-Line TB Treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be receiving first-line TB treatment with at least two of the following TB treatment drugs: isoniazid (INH), rifampin (RIF), rifabutin (RFB), ethambutol (EMB), pyrazinamide (PZA), or moxifloxacin (MFX).~Drugs will be administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants.
Study: NCT04518228
Drug: Second-Line TB Treatment
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be receiving second-line TB treatment with at least one of the following second-line TB treatment drugs:~* Levofloxacin (LFX) 750mg - 1000mg q.d.~* Clofazimine (CFZ) 100mg q.d.~* Linezolid (LZD) 300mg - 600mg q.d.~* Bedaquiline (BDQ) 200mg three times per week (t.i.w.)~* Delamanid (DLM) 100mg b.i.d.~* Moxifloxacin (MFX) 400mg or 800mg q.d., and at least one other second-line TB treatment drug under study~Drugs will be administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants.
Study: NCT05197842
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenously administered
Study: NCT05197842
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered
Study: NCT05501899
Drug: Levocarnitine
Normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adults, or patients ≥ 50 kg: 990 mg PO (by mouth) bis in die (BID, twice a day) Children, or patients \< 50 kg: 50 mg/kg/day PO divided BID (maximum daily dose of 2,000 mg)
Study: NCT05887336
Drug: Non preserved ocular lubricants
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Hyaluronic acid (HyloGel)~* Hyaluronic acid and Ectoin (Hylo Dual Intense)~* Hyaluronic acid and Trehalos (Theloz Duo)
Study: NCT05708859
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume matched Subcutaneous Solution
Study: NCT06569524
Drug: TQA2225/AP025 or TQA2225/AP025 Placebo 25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: To evaluate the efficacy and safety of TQA2225/AP025 (25mg) in patients with Non-Alcoholic Steatohepatitis (NASH)
Study: NCT06569524
Drug: TQA2225/AP025 or TQA2225/AP025 Placebo 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: To evaluate the efficacy and safety of TQA2225/AP025 (50mg) in patients with Non-Alcoholic Steatohepatitis (NASH)
Study: NCT05095922
Drug: Heart-Protecting Musk Pill
Normalized name: Tri-Heart Plus Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart-Protecting Musk Pill (pill, 45mg, three times a day, 3 months)
Study: NCT05095922
Drug: Calcium Dobesilate Capsules
Normalized name: calcium dobesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Dobesilate Capsules(capsule, 500mg, three times a day, 3 months)
Study: NCT06316570
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1(within 6.0 hours of onset, before or after intravenous thrombolysis) : Placebo of Ticagrelor (180mg) + Placebo of Aspirin (100mg), one dose;~Days 2-7: Placebo of Ticagrelor (90mg/time, twice/day) + open-label Aspirin (100mg/time, once/day) ;~Days 8-90: open-label Aspirin (100mg/time, once/day).
Study: NCT05064618
Drug: Am80
Approvals — FDA: no, EMA: no, PMDA: no
Description: medicine taken internally
Study: NCT04840186
Drug: 2nd line chemotherapy
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2nd line chemotherapy. Type of chemotherapy is determined by treating oncologist
Study: NCT06545617
Drug: BAT8006 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30\~60 minutes.
Study: NCT06674148
Drug: Qifangfeixian granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: The experimental group was treated with Qifangfixian granules
Study: NCT04837196
Drug: ASP7517
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV)
Study: NCT06273254
Drug: Entresto® (Sacubitril and Valsartan Tablets 49mg/51mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each tablet contains 48.6 mg sacubitril and 51.4 mg valsartan as sodium salt complex
Study: NCT06206720
Drug: Deuremidevir Hydrobromide for Suspension
Normalized name: hydrobromic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg BID group: 15 subjects will receive Deuremidevir Hydrobromide for Suspension once every 12 hours, total 10 times.~20 mg/kg BID group: 15 subjects will receive Deuremidevir Hydrobromide for Suspension once every 12 hours, total 10 times.~20 mg/kg TID group: 15 subjects will receive Deuremidevir Hydrobromide for Suspension 3 times every day, total 15 times.
Study: NCT06206720
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg BID group: 5 subjects will receive placebo once every 12 hours, total 10 times.~20 mg/kg BID group: 5 subjects will receive placebo once every 12 hours, total 10 times.~20 mg/kg TID group: 5 subjects will receive placebo 3 times every day, total 15 times.
Study: NCT05385978
Drug: APHD-012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distal jejunal-release dextrose beads (Aphaia technology, AT)
Study: NCT05385978
Drug: APHD-012P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distal jejunal-release placebo beads
Study: NCT05212740
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment will initiate with a dose of 0.5 mg/kg/day prednisolone for two weeks and the dose will halve in the next two weeks.
Study: NCT06146062
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 injections one week apart
Study: NCT05422066
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction Chemotherapy: 750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
Study: NCT05422066
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction Chemotherapy: 70mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
Study: NCT04755647
Drug: Nitric Oxide-Releasing Solution
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active antimicrobial
Study: NCT04755647
Drug: Saline solution, hypotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06639191
Drug: [177Lu]Lu-AKIR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient cohorts of a minimum of three and a maximum of 12 evaluable participants will be opened according to the decision tree defined in the protocol and will be consecutively completed. When one cohort has been completed and fully evaluated, the next cohort will be opened after all participants in the previous cohort have received at least one dose of the IMP without dose-limiting toxicities during a follow-up period of at least six weeks.~The \[177Lu\]Lu-AKIR001 protein mass dose and activity are predefined for each cohort, and could be adjusted according to the results of previous cohort(s) to ensure the safety of participants. The initial design of the trial encompasses five cohorts to escalate both \[177Lu\]Lu-AKIR001 pmd, from 50 mg to 100 mg, and activity, from 0.75 to 3.0 GBq.
Study: NCT06641388
Drug: Ebronucimab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebronucimab subcutaneous injection
Study: NCT06636578
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: will not receive any regional anesthesia and only will receive I.V. fentanyl 1μg/kg/hr.
Study: NCT06630130
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Neoadjuvant; Capecitabine 1000mg/m2 PO BID on D1-D14, Q3W for 3 cycles~* Adjuvant; Capecitabine 1000mg/m2 PO BID on D1-D14, Q3W for 4 cycles (up to 3 months)
Study: NCT05525520
Drug: EP547
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily
Study: NCT05525520
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily
Study: NCT06570746
Drug: Sedative
Normalized name: Sedative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation is applied before the procedure
Study: NCT06569459
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy and immunotherapy in the treatment of patients with unresectable locally advanced esophageal squamous cell carcinoma
Study: NCT05860244
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Syrup for 6 months
Study: NCT06563869
Drug: PEG-rhG-GSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycolylated recombinant human granulocyte stimulating factor （6mg）will be given 24 hours after the end of chemotherapy.
Study: NCT05583955
Drug: NOE-105
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escalating dose levels of NOE-105 will be given and maximum tolerated dose will be maintained
Study: NCT05583955
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating dose levels of matching Placebo will be given